Spyglass Pharma Inc (SGP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2001 | 12-2000 | |
| Cash Flows From Operating Activities | ||
| Net Income | 1,943,000 | 2,423,000 |
| Depreciation Amortization | 320,000 | 299,000 |
| Accounts receivable | -434,000 | -418,000 |
| Other Working Capital | -251,000 | -211,000 |
| Other Operating Activity | 934,000 | 418,000 |
| Operating Cash Flow | $2,512,000 | $2,511,000 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -759,000 | -763,000 |
| Purchase Of Investment | -162,000 | -104,000 |
| Sale Of Investment | 33,000 | 60,000 |
| Other Investing Activity | 25,000 | -41,000 |
| Investing Cash Flow | $-863,000 | $-848,000 |
| Cash Flows From Financing Activities | ||
| Change In Short Term Borrowing | N/A | 280,000 |
| Debt Issued | 8,000 | 106,000 |
| Common Stock Repurchased | -34,000 | -855,000 |
| Dividend Paid | -911,000 | -802,000 |
| Other Financing Activity | -390,000 | 133,000 |
| Financing Cash Flow | $-1,327,000 | $-1,138,000 |
| Exchange Rate Effect | -3,000 | -4,000 |
| Beginning Cash Position | 2,397,000 | 1,876,000 |
| End Cash Position | 2,716,000 | 2,397,000 |
| Net Cash Flow | $319,000 | $521,000 |
| Free Cash Flow | ||
| Operating Cash Flow | 2,512,000 | 2,511,000 |
| Capital Expenditure | -759,000 | -763,000 |
| Free Cash Flow | 1,753,000 | 1,748,000 |